Novartis

Novartis AG will cut stake in Indian arm to meet SEBI norms

28 Mar 2013

Novartis expects ‘negative’ SC verdict in Glivec patent case

28 Mar 2013

Chairman steps down even as Novartis posts profit rise

24 Jan 2013

Cipla appoints Novartis' Subhanu Saxena as new CEO

22 Nov 2012

Cipla has appointed the former CEO and country president of Novartis UK, Subhanu Saxena, as its new CEO

Novartis receives FDA approval to make first cell-culture vaccine in US for seasonal influenza

21 Nov 2012

Supreme Court asks Novartis to cut price of Glivec

13 Sep 2012

Glivec is `special’, Novartis argues in Supreme Court

11 Sep 2012

Novartis restructures US operations, to cut 1,960 jobs

14 Jan 2012

Mylan launches first generic version of Novartis' dementia drug Exelon

27 Oct 2011

Novartis to eliminate 2,000 jobs, close two sites in Europe

25 Oct 2011

The job cut, which is 1 per cent of Novart's workforce of around 120,000, is expected to generate annual savings of more than $200 million.

European regulator launches antitrust probe against Novartis and J&J

24 Oct 2011

Novartis to file breast cancer combination drug Afinitor

05 Jul 2011

GW Pharma, Novartis sign deal to market cannabis derivative

12 Apr 2011

Novartis to acquire cancer diagnostics company Genoptix for $470 million

25 Jan 2011

Novartis plans $500 million investment in Russia

21 Dec 2010

ImmunoGen to collaborate with Novartis on novel cancer treatment

12 Oct 2010

Novartis aqnnounces novel antimalarial drug

06 Sep 2010

Quark Pharmaceuticals inks $680 million drug licensing deal with Novartis

19 Aug 2010

Novartis penalised $250 million for gender bias against women

20 May 2010

Novartis acquires generic respiratory drug maker Oriel Therapeutics

19 Apr 2010

Alcon directors deride Novartis offer as grossly inadequate

20 Jan 2010

Novartis acquires 52 per cent additional stake in Alcon for $28.1 billion

04 Jan 2010

Novartis, which acquired a 25 per cent stake in Nestle-owned Alcon for $11 billion in April 2008, is exercising its call option to buy an additional 52 per cent stake for $180 per share in the eye-care giant.

Novartis acquires Corthera, gets global rights to new heart drug

23 Dec 2009

IBM, Novartis, Vodafone in novel venture to combat malaria in Africa

15 Dec 2009

Novartis gains rights to two oral investigational therapies for life-threatening blood disorders, cancers

25 Nov 2009